Topics

Companies Related to "Targeting Neuraminidase Lead Universal Vaccine" [Most Relevant Company Matches] RSS

15:54 EST 10th December 2019 | BioPortfolio

Here are the most relevant search results for "Targeting Neuraminidase Lead Universal Vaccine" found in our extensive corporate database of over 50,000 company records.

Showing "Targeting Neuraminidase Lead Universal Vaccine" Companies 1–25 of 2,000+

Relevant

Osivax

Osivax’s mission is to revolutionize influenza prevention with a universal flu vaccine for both current and future Influenza A and B infections by leveraging its unique oligoDOM® technology platform. The most advanced candidate, a broad-spectrum A-strain flu vaccine is in Phase 1 clinical development. Osivax is focused on providing proof-of-concept in Influenza A firstly to save lives and...


Hawaii Biotech, Inc.

Hawaii Biotech, Inc. is a privately held biopharmaceutical company focused on vaccine research and development. The company is targeting first world vaccines with potentially large markets and attractive margins: a West Nile vaccine targeting the U.S. and Canada; and a dengue fever vaccine for travelers from first world countries to dengue endemic areas. The Company’s vaccine technology was feat...

FluGen Inc.

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory of Dr. Yoshihiro Kawaoka at the University of Wisconsin, Madison. It’s lead product candidate, RedeeFlu™ is a universal flu vaccine which is based on the knowledge that a ...


Pharmexa

Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epito...

Inviragen, Inc. and PharmaJet, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

Inviragen, Inc. and Duke-NUS

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease, chikungunya and Japanese encephalitis which affect millions of individuals in Asia. Vaccines in ...

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMU...

BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Flu is the most common infectious disease, caused by countless flu strains, as the virus mutates unpredictably and frequently. Currently, seasonal flu vaccines are re-formulated each year a...

Acambis

Acambis recognises the value of highly focused marketing efforts and is initially targeting the world's single largest vaccine market – the US – to maximise the return on our investment. In 2003, we acquired a North American vaccine sales, promotion and distribution company, Berna Products Corporation (BPC). BPC has the exclusive North American sales and distribution rights to the world's only...

Universal Protection Service

Founded in 1965, Universal Protection Service (UPS) combines an innovative mix of tradition with cutting edge systems and technology to keep pace with the ever-evolving needs of today's business environments. Headquartered in Santa Ana, Calif., with offices located throughout Arizona, California, Colorado and Washington, UPS employs hands-on, highly experienced management teams and continuous trai...

Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon™ technology enables the design of “universal” vaccines capable of protecting against multiple – including newly emergent, unknown – stra...

Universal American Corp.

Universal American, through our family of healthcare companies, offers benefit plans designed to promote collaboration among our members and their healthcare professionals. This Healthy CollaborationSM improves, each day, the health and well-being of more than two million older and disabled Americans. For more information on Universal American, please visi...

Affinivax, Inc.

Affinivax is advancing a next generation vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challenging infectious diseases. Backed by an investment from the Bill & Melinda Gates Foundation, and working with world experts in vaccine discovery and development, Affinivax is focused on creati...

Inviragen, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Affinivax Inc.

Affinivax is advancing a next generation conjugate vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challenging infectious diseases. Backed by an investment from the Bill & Melinda Gates Foundation and working with world experts in vaccine discovery and development, Affinivax is focused ...

Universal Pasteurization Company LLC

Headquartered in Villa Rica, Ga., Universal Pasteurization Company, LLC (www.universalpasteurization.com), as well as its affiliated business Universal Cold Storage, LLC is dedicated to ensuring the safety and quality of foods and beverages. As a customer-centric service provider of high pressure processing (HPP), Universal Pasteurization’s four U.S. locatio...

Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in developing and delivering state-of-the-art, organic light emitting diode (OLED) technologies, materials and services to the display and lighting industries. To learn more about Universal Display Corporation, please visit http://www.oled.com.

Vaxxas

Vaxxas is a privately-held biotechnology company focused on enhancing the performance of existing and next generation vaccines with its proprietary Nanopatch™ technology platform. Vaxxas’ Nanopatch contains an ultra-high density array of projections – invisible to the naked human eye – that are dry-coated with vaccine. Application of the ...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

Themis

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine technology has created a powerful platform and a growing pipeline addressing a broad range of infectious disease...

Universal Health Care Group, Inc.

Universal Health Care Group is the parent company of Universal Health Care, Inc., a managed care company that has been providing Medicare Advantage Health Plans to Medicare eligible beneficiaries since 2003 – most notably the “Medicare Masterpiece® (HMO)” and “Medicare Masterpiece® (PPO)” plans, as well as Florida Medicaid be...

Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already...

Tm Bioscience

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, toxicology, gynecology and other debilitating genetic disorders. The lead product from Tm Bioscience is the Tm100 Universal Array, a microarray "operating system" capable of combining any set of 100 single DNA tests and p...


More From BioPortfolio on "Targeting Neuraminidase Lead Universal Vaccine"

Quick Search

Corporate Database Quicklinks